BACKGROUND: Lactic acid bacteria have been suggested for use in the prevention of relapse of ulcerative colitis and of recurrent pouchitis. These strains may not damage the protective intestinal mucus glycoproteins. METHODS: Lactobacillus casei strain GG and strains isolated from a commercial fermented product (Lactobacillus acidophilus, Bifidobacterium bifidum, and a mesophylic lactic culture) were cultured in vitro on hog gastric mucin and human intestinal glycoproteins. Furthermore, germ-free rats were mono-associated with Lactobacillus GG and poly-associated with the other strains. Glycoproteins were isolated from rat distal ileum, cecum, and colon. Mucus degradation was established by assaying carbohydrates (hexosamines, hexoses, pentoses), proteins, and blood group antigenicity. RESULTS: All strains colonized the intestinal mucus but were not found in the deep crypts. Degradation of mucus glycoproteins was observed neither in vitro nor in vivo. CONCLUSION: The tested strains do not break down intestinal mucus glycoproteins and thus far are safe to use for therapy.
BACKGROUND:Lactic acid bacteria have been suggested for use in the prevention of relapse of ulcerative colitis and of recurrent pouchitis. These strains may not damage the protective intestinal mucus glycoproteins. METHODS:Lactobacillus casei strain GG and strains isolated from a commercial fermented product (Lactobacillus acidophilus, Bifidobacterium bifidum, and a mesophylic lactic culture) were cultured in vitro on hog gastric mucin and human intestinal glycoproteins. Furthermore, germ-free rats were mono-associated with Lactobacillus GG and poly-associated with the other strains. Glycoproteins were isolated from rat distal ileum, cecum, and colon. Mucus degradation was established by assaying carbohydrates (hexosamines, hexoses, pentoses), proteins, and blood group antigenicity. RESULTS: All strains colonized the intestinal mucus but were not found in the deep crypts. Degradation of mucus glycoproteins was observed neither in vitro nor in vivo. CONCLUSION: The tested strains do not break down intestinal mucus glycoproteins and thus far are safe to use for therapy.
Authors: Isabel Gómez-Hurtado; Arlette Santacruz; Gloria Peiró; Pedro Zapater; Ana Gutiérrez; Miguel Pérez-Mateo; Yolanda Sanz; Rubén Francés Journal: PLoS One Date: 2011-07-29 Impact factor: 3.240
Authors: Geert Huys; Nadine Botteldoorn; Frank Delvigne; Luc De Vuyst; Marc Heyndrickx; Bruno Pot; Jean-Jacques Dubois; Georges Daube Journal: Mol Nutr Food Res Date: 2013-06-25 Impact factor: 5.914
Authors: P D Cani; S Possemiers; T Van de Wiele; Y Guiot; A Everard; O Rottier; L Geurts; D Naslain; A Neyrinck; D M Lambert; G G Muccioli; N M Delzenne Journal: Gut Date: 2009-02-24 Impact factor: 23.059
Authors: Estefanía Muñoz-Atienza; Beatriz Gómez-Sala; Carlos Araújo; Cristina Campanero; Rosa del Campo; Pablo E Hernández; Carmen Herranz; Luis M Cintas Journal: BMC Microbiol Date: 2013-01-24 Impact factor: 3.605